Antibody‐Drug‐Conjugate Therapy for Hematological Cancers: Matching Cell Biology with Clinical Benefit
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody‐Drug‐Conjugate Therapy for Hematological Cancers: Matching Cell Biology with Clinical Benefit
Authors
Keywords
-
Journal
ADVANCED FUNCTIONAL MATERIALS
Volume -, Issue -, Pages 2100032
Publisher
Wiley
Online
2021-05-24
DOI
10.1002/adfm.202100032
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
- (2021) Gilles Salles et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Population Pharmacokinetics, Efficacy, and Safety of Moxetumomab Pasudotox in Patients With Relapsed or Refractory Hairy Cell Leukemia
- (2020) Denison Kuruvilla et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- 3′-sialyllactose targets cell surface protein, SIGLEC-3, and induces megakaryocyte differentiation and apoptosis by lipid raft-dependent endocytosis
- (2020) Sun-Hyung Ha et al. GLYCOCONJUGATE JOURNAL
- A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
- (2020) Lijie Xing et al. LEUKEMIA
- Soluble CD30, the Immune Response, and Acute Rejection in Human Kidney Transplantation: A Systematic Review and Meta-Analysis
- (2020) Mohammad Mirzakhani et al. Frontiers in Immunology
- Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
- (2020) Colby S. Shemesh et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin
- (2020) Talha Badar et al. Clinical Lymphoma Myeloma & Leukemia
- Next-generation Antibody-drug Conjugates (ADCs): Exploring New Frontiers with Chemical Approaches
- (2020) Yasuaki Anami et al. JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN
- Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
- (2020) Hans C. Lee et al. LEUKEMIA
- Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
- (2020) Daniel J. DeAngelo et al. Blood Cancer Journal
- Rapid Evaluation of Antibody Fragment Endocytosis for Antibody Fragment–Drug Conjugates
- (2020) Eunhee G. Kim et al. Biomolecules
- Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
- (2020) Yafit Segman et al. LEUKEMIA & LYMPHOMA
- Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
- (2020) Paul G. Richardson et al. Blood Cancer Journal
- Antibody–drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin
- (2020) J. M. Burke et al. Expert Review of Clinical Pharmacology
- Brentuximab Vedotin and ESHAP is Highly Effective as Second-Line Therapy for Hodgkin Lymphoma Patients (Long-Term Results of a Trial by the Spanish GELTAMO Group)
- (2019) R Garcia-Sanz et al. ANNALS OF ONCOLOGY
- Acquired Resistance to Antibody-Drug Conjugates
- (2019) Denis Collins et al. Cancers
- Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
- (2019) Franck Morschhauser et al. Lancet Haematology
- A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations
- (2019) Allison M. L. Nixon et al. Scientific Reports
- Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
- (2019) May Garrett et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance
- (2019) Megan R. Paul et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma
- (2019) Sundar Jagannath et al. Clinical Lymphoma Myeloma & Leukemia
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
- (2019) Hagop M. Kantarjian et al. CANCER
- Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
- (2019) Tiantian Ma et al. ANNALS OF HEMATOLOGY
- Pharmacokinetic/ Pharmacodynamic Modeling To Support The Re‐Approval Of Gemtuzumab Ozogamicin
- (2019) Luke K. Fostvedt et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
- (2019) Hervé Tilly et al. LANCET ONCOLOGY
- Preclinical activity of the antibody‐drug conjugate denintuzumab mafodotin (SGN‐CD19A) against pediatric acute lymphoblastic leukemia xenografts
- (2019) Luke Jones et al. PEDIATRIC BLOOD & CANCER
- Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
- (2019) Haiming Chen et al. LEUKEMIA RESEARCH
- Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
- (2019) Marijke Timmers et al. Frontiers in Immunology
- Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
- (2019) Robert Chen et al. CLINICAL CANCER RESEARCH
- Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial
- (2018) Anna Candoni et al. AMERICAN JOURNAL OF HEMATOLOGY
- Antibody–Drug Conjugates for Cancer Treatment
- (2018) John M. Lambert et al. Annual Review of Medicine
- The challenge of drug resistance in cancer treatment: a current overview
- (2018) Michail Nikolaou et al. CLINICAL & EXPERIMENTAL METASTASIS
- FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
- (2018) Emily Y. Jen et al. CLINICAL CANCER RESEARCH
- CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas
- (2018) Marcus P. Watkins et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
- (2018) Marek Trněný et al. HAEMATOLOGICA
- FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia
- (2018) Kelly J. Norsworthy et al. ONCOLOGIST
- A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
- (2018) Marek Trněný et al. HAEMATOLOGICA
- A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML
- (2018) Amir T. Fathi et al. BLOOD
- Review on Targeted Drug Delivery Carriers Used in Nanobiomedical Applications
- (2018) Shashiprabha Punyakantha Dunuweera et al. Current Nanoscience
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
- (2018) Steven Horwitz et al. LANCET
- Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells
- (2018) Krista Kinneer et al. LEUKEMIA
- Utilization of Multi-Immunization and Multiple Selection Strategies for Isolation of Hapten-Specific Antibodies from Recombinant Antibody Phage Display Libraries
- (2017) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531
- (2017) Jatinder K. Lamba et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- (2017) H Miles Prince et al. LANCET
- CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
- (2017) Arnab Ghosh et al. LEUKEMIA & LYMPHOMA
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Modulating IgG effector function by Fc glycan engineering
- (2017) Tiezheng Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of a facile antibody–drug conjugate platform for increased stability and homogeneity
- (2017) Nimish Gupta et al. Chemical Science
- Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin
- (2016) Alison M. Betts et al. AAPS Journal
- Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab
- (2016) Yasmin Abaza et al. BLOOD
- Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
- (2016) Binsah George et al. Immunotherapy
- Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding
- (2016) Rami N Al-Rohil et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
- (2016) Valentina Cappello et al. Scientific Reports
- Antibody-targeted drugs and drug resistance—Challenges and solutions
- (2015) LeeRon Shefet-Carasso et al. DRUG RESISTANCE UPDATES
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
- (2015) M Pfeifer et al. LEUKEMIA
- CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
- (2015) R. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Cancer-treatment-induced neurotoxicity—focus on newer treatments
- (2015) Jacqueline B. Stone et al. Nature Reviews Clinical Oncology
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
- (2014) Nancy L Bartlett et al. Journal of Hematology & Oncology
- (R)Evolutionary Therapy: The Potential of Immunotherapy to Fulfill the Promise of Personalized Cancer Treatment
- (2014) R. A. Madan et al. JNCI-Journal of the National Cancer Institute
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
- (2013) D. Li et al. MOLECULAR CANCER THERAPEUTICS
- Cis and Trans Regulatory Mechanisms Control AP2-Mediated B Cell Receptor Endocytosis via Select Tyrosine-Based Motifs
- (2013) Kathleen Busman-Sahay et al. PLoS One
- B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention
- (2013) H.-W. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling
- (2013) J. Muller et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues
- (2012) Astrid Schweizer et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted drug delivery for cancer therapy: the other side of antibodies
- (2012) Michael A Firer et al. Journal of Hematology & Oncology
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Genetic heterogeneity and cancer drug resistance
- (2012) Nicholas C Turner et al. LANCET ONCOLOGY
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- The development of pyrrolobenzodiazepines as antitumour agents
- (2011) John A Hartley EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
- (2011) Sara Raponi et al. LEUKEMIA & LYMPHOMA
- CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells
- (2010) M. K. O'Reilly et al. JOURNAL OF IMMUNOLOGY
- CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma
- (2009) Akihiro Takeshita et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML
- (2009) Petra Haag et al. EXPERIMENTAL HEMATOLOGY
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started